Patents by Inventor Kyle BOTSCH

Kyle BOTSCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11920166
    Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: March 5, 2024
    Assignee: RENEW BIOPHARMA, INC.
    Inventors: Kyle Botsch, Craig Behnke, Karla Gonzalez, Matthew Saunders, Michael Mendez
  • Publication number: 20230203455
    Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.
    Type: Application
    Filed: July 20, 2022
    Publication date: June 29, 2023
    Inventors: Kyle BOTSCH, Craig BEHNKE, Karla GONZALEZ, Matthew SAUNDERS, Michael MENDEZ
  • Publication number: 20230029027
    Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant prenyltransferase enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to the wild type prenyltransferase. The disclosure also provides methods of preparing such recombinant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.
    Type: Application
    Filed: April 13, 2020
    Publication date: January 26, 2023
    Inventors: Michael MENDEZ, Joseph NOEL, Michael BURKART, Jeremy LANOISELEE, Kyle BOTSCH, Matthew SAUNDERS
  • Publication number: 20220411766
    Abstract: Described herein are prenyltransferases including non-natural variants thereof having at least one amino acid substitution as compared to its corresponding natural or unmodified prenyltransferases and that are capable of at least two-fold greater rate of formation of cannabinoids such as cannabigerolic acid, cannabigerovarinic acid, cannabigerorcinic acid, and cannabigerol, as compared to a wild type control. Prenyltransferase variants also accept different hydrophobic substrates (e.g., “donor” molecules), compared to wild type controls, to create different minor and novel cannabinoids. Prenyltransferase variants also demonstrated regioselectivity to desired cannabinoid isomers such as CBGA (3-GOLA), 3-GDVA, 3-GOSA, and CBG (2-GOL). The prenyltransferase variants can be used to form prenylated aromatic compounds, and can be expressed in an engineered microbe having a pathway to such compounds, which include 3-GOLA, 3-GDVA, 3-GOSA, and CBG.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 29, 2022
    Inventors: Michael J. MENDEZ, Kyle BOTSCH, Tasha ALTHEIDE, Matthew SAUNDERS
  • Publication number: 20220364066
    Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof. In one aspect, a variant cannabinoid synthase or an active fragment thereof is provided comprising a non-naturally occurring amino acid sequence relative to a wild-type cannabinoid synthase or an active fragment thereof which acts on a substrate to produce an altered amount of a cannabinoid relative to an amount of the cannabinoid produced by the wild-type cannabinoid synthase or active fragment thereof.
    Type: Application
    Filed: October 22, 2020
    Publication date: November 17, 2022
    Inventors: Kyle BOTSCH, Craig BEHNKE, Karla GONZALEZ, Matthew SAUNDERS, Michael J. MENDEZ, Jeremy LANOISELEE
  • Publication number: 20210301267
    Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.
    Type: Application
    Filed: October 27, 2020
    Publication date: September 30, 2021
    Inventors: Michael MENDEZ, Joseph NOEL, Michael BURKART, Jeremy LANOISELEE, Kyle BOTSCH, Matthew SAUNDERS
  • Publication number: 20210238561
    Abstract: Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 5, 2021
    Inventors: Kyle BOTSCH, Craig BEHNKE, Karla GONZALEZ, Matthew SAUNDERS, Michael MENDEZ
  • Patent number: 10894952
    Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: January 19, 2021
    Assignee: RENEW BIOPHARMA, INC.
    Inventors: Michael Mendez, Joseph Noel, Michael Burkart, Jeremy Lanoiselee, Kyle Botsch, Matthew Saunders
  • Publication number: 20200123511
    Abstract: The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.
    Type: Application
    Filed: November 13, 2019
    Publication date: April 23, 2020
    Inventors: Michael MENDEZ, Joseph NOEL, Michael BURKART, Jeremy LANOISELEE, Kyle BOTSCH, Matthew SAUNDERS